Announcement of Resolutions of the First Extraordinary Shareholders Meeting in 2026

Securities code: 688098 Securities abbreviation: Shenlian Biotech Announcement number: 2026-009 Shenlian Biopharmaceutical (Shanghai) Co., Ltd.

The company's board of directors and all directors guarantee that the announcement does not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.

Important content reminder:

 Whether any motions were rejected at this meeting: None

1. Meeting convening and attendance

(1) Time of the shareholders’ meeting: March 12, 2026

(2) The location of the shareholders' meeting: Conference room on the first floor of the company's complex building, No. 48 Jiangchuan East Road, Minhang District, Shanghai

(3) Information on the ordinary shareholders, special voting rights shareholders, preference shareholders whose voting rights have been restored and the number of voting rights they hold present at the meeting:

1. Number of shareholders and proxies attending the meeting 122 Number of ordinary shareholders 122

2. Number of voting rights held by shareholders attending the meeting 241,044,743 Number of voting rights held by ordinary shareholders 241,044,743

3. The ratio of the number of voting rights held by shareholders attending the meeting to the number of voting rights of the company

59.1917 (%)

Proportion of the number of voting rights held by ordinary shareholders to the number of voting rights of the company (%) 59.1917

(4) Whether the voting method complies with the provisions of the Company Law and the company's articles of association, and the status of the shareholders' meeting, etc.

This shareholders' meeting was convened by the company's board of directors and chaired by Chairman Nie Dongsheng. The meeting adopted a combination of on-site voting and online voting for voting. The convening and convening procedures of this shareholders' meeting, the qualifications of the persons attending the meeting and the qualifications of the convener, the voting procedures and voting results of the meeting are all in compliance with the provisions of the Company Law and the Articles of Association.

(5) Attendance of company directors and board secretary

1. The company has 9 current directors and 9 people present;

2. Ms. Yu Haixia, secretary of the company's board of directors, attended this meeting. All senior executives of the company and Ms. Lin Shujing, general manager of Yangzhou Shizhiyuan Biotechnology Co., Ltd., also attended this meeting.

2. Proposal review status

(1) Non-cumulative voting proposals

1. Proposal Name: "Proposal on Re-appointment of Accounting Firm"

Review result: Passed

Voting status:

Agree Objection Abstaining shareholder type Proportion Proportion Number of votes Number of votes Number of votes

(%) (%) (%) Ordinary shares 240,726,932 99.8681 272,711 0.1131 45,100 0.0188

2. Proposal Name: "Proposal on Acquiring Controlling Interests in Associated Companies and Launching New Businesses and Related Transactions" Deliberation Result: Passed

Voting status:

Agree Objection Abstaining shareholder type Proportion Proportion Number of votes Number of votes Number of votes

(%) (%) (%) Ordinary shares 113,932,599 99.3781 685,841 0.5982 27,100 0.0236

(2) When major matters are involved, the voting status of less than 5% of shareholders should be explained.

Agree, object, abstain

Proposal name Proportion

Order Number of votes Number of votes Proportion (%) Number of votes Proportion (%)

(%)

No.

"About the Acquisition

Associated company control

Equity and development 62,364,3

2 98.8697 685,841 1.0873 27,100 0.0430New business and customs 27

joint transaction agreement

case"

(3) Explanation of relevant circumstances regarding voting on motions

1. The votes of small and medium-sized investors were counted separately for the second proposal at this meeting.

2. The second proposal at this meeting is a related transaction, and related shareholders Yang Yufang, Yang Congzhou and Wang Dongliang have abstained from voting.

3. Lawyer’s testimony

1. The law firm witnessing this shareholder meeting: Shanghai AllBright Law Firm

Lawyers: Cao Lihui, Qiu Jiahua

2. Lawyer’s concluding comments:

Lawyers from our firm believe that the convening and holding procedures of the company’s shareholders’ meeting complied with the provisions of laws, regulations and the Articles of Association; the qualifications of the convener and those attending the meeting were legal and valid; the voting procedures complied with the provisions of the Articles of Association, and the voting results were legal and valid.

Announcement is hereby made.

Board of Directors of Shenlian Biopharmaceutical (Shanghai) Co., Ltd.

March 13, 2026